A new experimental drug called Cadd4 reduced heart disease plaque buildup by targeting a protein called PCSK9 in mouse studies. According to Gram Research analysis, Cadd4 not only decreased plaque formation but also made existing plaque stronger and less likely to rupture by increasing collagen content and reducing inflammation. The drug worked better than a currently approved heart disease medication at improving plaque composition, suggesting a new approach to heart disease treatment that reduces inflammation independent of cholesterol levels.
Scientists have developed a new experimental drug called Cadd4 that works differently than current heart disease treatments. Instead of just lowering cholesterol, Cadd4 targets a protein called PCSK9 and makes the body break it down. In studies with mice, Cadd4 reduced dangerous plaque buildup in arteries and made the plaque that did form stronger and less likely to rupture. The drug also reduced inflammation in blood vessels. Gram Research analysis shows this approach could offer a new way to protect hearts beyond traditional cholesterol-lowering medications.
Key Statistics
A 2026 research article published in BMC Medicine found that Cadd4, a new experimental drug, significantly reduced atherosclerotic plaque area in mice after 12 weeks of treatment and outperformed the approved drug alirocumab at suppressing dangerous proteins that weaken plaque structure.
According to a 2026 study of Cadd4 in mice with atherosclerosis, the experimental drug increased collagen content in arterial plaques by enhancing plaque stability while simultaneously reducing inflammation markers through inhibition of the NF-κB/TNF-α signaling pathway.
A 2026 laboratory study found that Cadd4 induced dose-dependent degradation of PCSK9 protein in three different cell types and significantly attenuated inflammatory responses in cells stimulated with lipopolysaccharide, suggesting broad anti-inflammatory effects.
Research published in BMC Medicine in 2026 demonstrated that Cadd4’s anti-atherosclerotic effects occurred through lipid-independent mechanisms, meaning the drug improved heart plaque composition without changing overall blood cholesterol levels.
The Quick Take
- What they studied: Whether a new experimental drug called Cadd4 could reduce heart disease by breaking down a protein that contributes to plaque buildup in arteries
- Who participated: Laboratory studies used three types of human and mouse cells. Animal testing used mice genetically modified to develop heart disease when fed a high-fat diet, similar to how humans develop atherosclerosis
- Key finding: Cadd4 reduced plaque buildup in arteries by 12 weeks and made existing plaque stronger by increasing collagen content, while also reducing inflammation—effects that were better than a current approved drug called alirocumab
- What it means for you: This research is early-stage and only tested in mice, so it’s too soon to know if it will work in humans. However, it suggests a new approach to heart disease treatment that works through inflammation reduction rather than just cholesterol lowering. Talk to your doctor about current proven treatments for heart disease
The Research Details
Researchers created a new type of drug called a PROTAC, which is like a molecular scissors that targets and destroys specific proteins. They designed Cadd4 to specifically destroy PCSK9, a protein that interferes with the body’s ability to remove cholesterol from the blood. First, they tested Cadd4 in laboratory dishes containing three different types of cells—immune cells, blood vessel cells, and endothelial cells that line blood vessels. They measured how well Cadd4 broke down PCSK9 and whether it reduced inflammation markers.
Next, they moved to animal testing using mice that were genetically engineered to develop heart disease similar to humans. These mice were fed a high-fat diet to accelerate plaque buildup. Half the mice received Cadd4 injections every two days for 12 weeks, while the other half received alirocumab (a currently approved heart disease drug) once weekly. Researchers then examined the mice’s arteries to measure plaque size, plaque composition, and inflammation levels.
The study measured multiple outcomes including how much PCSK9 was destroyed, how much plaque formed, the strength of plaques, and levels of inflammatory markers. They compared results between Cadd4 and alirocumab to see which was more effective.
This research approach matters because current cholesterol-lowering drugs work by one main mechanism. Cadd4 appears to work through a different pathway—reducing inflammation in blood vessels independent of cholesterol levels. This suggests that combining different approaches might help more patients. Additionally, the PROTAC technology is relatively new, so demonstrating it works for heart disease could open doors to treating other diseases with similar protein-targeting drugs.
This study has several important limitations to understand. It was conducted in mice, not humans, so results may not translate directly. The sample size of mice wasn’t specified in the abstract. The study was relatively short (12 weeks), so long-term safety and effectiveness remain unknown. The drug was given by injection, which may not be practical for long-term human use. The research was published in BMC Medicine, a reputable peer-reviewed journal, which is a positive indicator. However, this is early-stage research and would need to progress through multiple phases of human testing before becoming available as a treatment.
What the Results Show
Cadd4 successfully broke down PCSK9 protein in all three types of cells tested in the laboratory, and this effect increased with higher doses. When mice received Cadd4 injections for just two weeks, PCSK9 levels dropped significantly in both their livers and arteries. After 12 weeks of treatment, mice receiving Cadd4 developed significantly less plaque in their arteries compared to untreated mice.
More importantly, the plaque that did form was structurally stronger and less dangerous. Cadd4 increased collagen content in plaques, which makes them more stable and less likely to rupture and cause a heart attack. The drug also reduced inflammation inside plaques, which is a key factor in plaque rupture. When compared directly to alirocumab (a currently approved drug), Cadd4 performed better at reducing dangerous proteins called matrix metalloproteinases that weaken plaque structure.
The anti-inflammatory effects appeared to work through a specific pathway called NF-κB/TNF-α, which is involved in inflammation throughout the body. By blocking this pathway, Cadd4 reduced inflammatory signals in blood vessel cells. Interestingly, Cadd4 achieved these benefits without changing overall blood cholesterol levels, suggesting it works through inflammation reduction rather than cholesterol lowering.
The study found that Cadd4’s benefits were consistent across different cell types and tissues, suggesting the drug works reliably in multiple locations. The drug was well-tolerated during the 12-week study period with no reported safety concerns, though longer-term safety data is needed. The fact that Cadd4 worked better than alirocumab at improving plaque composition suggests this new approach may offer advantages over current treatments. The lipid-independent mechanism (working without changing cholesterol) is significant because it suggests Cadd4 could potentially be combined with cholesterol-lowering drugs for additional benefit.
Current approved treatments for high cholesterol and heart disease primarily work by lowering LDL cholesterol levels. Alirocumab, the drug used for comparison, works by blocking PCSK9 but appears to work mainly through cholesterol reduction. This study suggests that targeting PCSK9 through a different mechanism (protein degradation rather than blocking) may provide additional anti-inflammatory benefits. The PROTAC technology is newer than traditional drug approaches, and this is one of the first demonstrations of its effectiveness for heart disease. Previous research has shown that inflammation plays a major role in heart disease beyond just cholesterol, so this lipid-independent approach fills an important gap in current treatment options.
This study has several important limitations. First, it was conducted entirely in mice, and mouse models don’t perfectly replicate human heart disease. Second, the study duration was only 12 weeks, so we don’t know about long-term safety or effectiveness. Third, the drug was given by injection, which may not be practical for long-term human use. Fourth, the study didn’t measure actual heart attacks or deaths, only plaque characteristics. Fifth, the sample size of mice wasn’t clearly specified. Sixth, this is early-stage research and hasn’t been tested in humans yet. Finally, the study didn’t examine potential side effects in detail or test different doses to find the optimal amount.
The Bottom Line
This research is too early-stage to recommend Cadd4 for human use. Current proven treatments for high cholesterol and heart disease include statins, PCSK9 inhibitors like alirocumab, and lifestyle changes. Continue following your doctor’s current treatment plan. If you have heart disease or high cholesterol, discuss with your healthcare provider which proven treatments are right for you. This research may eventually lead to new treatment options, but that’s likely years away. Confidence level: Low—this is animal research only.
This research is most relevant to people with high cholesterol, atherosclerosis, or heart disease who may benefit from new treatment options. Researchers studying heart disease, inflammation, and drug development should pay attention to this PROTAC technology. Pharmaceutical companies may be interested in developing similar drugs. People currently taking cholesterol-lowering medications don’t need to change anything based on this research. This is not relevant to people without heart disease risk factors.
If Cadd4 moves forward in development, it would typically take 5-10 years before becoming available to patients. First, it would need safety testing in humans (Phase 1), then effectiveness testing (Phase 2), then large-scale confirmation (Phase 3), and finally FDA approval. Even if everything goes smoothly, realistic timeline is 7-10 years minimum. This research represents an early proof-of-concept stage.
Frequently Asked Questions
What is PCSK9 and why do doctors care about it for heart disease?
PCSK9 is a protein that prevents the body from removing cholesterol from the blood, leading to plaque buildup in arteries. Blocking or destroying PCSK9 helps reduce cholesterol and heart disease risk. Current drugs like alirocumab block PCSK9, while Cadd4 destroys it, potentially offering additional benefits.
Is Cadd4 available as a treatment for heart disease right now?
No, Cadd4 is still in early research stages and has only been tested in mice. It would need years of human testing and FDA approval before becoming available. Current proven treatments for high cholesterol and heart disease include statins and PCSK9 inhibitors like alirocumab.
How does Cadd4 work differently than current heart disease drugs?
Cadd4 uses PROTAC technology to destroy PCSK9 protein rather than just blocking it. More importantly, it reduces inflammation in blood vessels independent of cholesterol levels. Current drugs mainly work by lowering cholesterol, so this represents a different approach to protecting heart health.
Could Cadd4 be combined with other heart disease medications?
That’s unknown at this stage. The research only tested Cadd4 alone in mice. Future human studies would need to examine whether combining Cadd4 with statins or other cholesterol drugs provides additional benefits. Always discuss medication combinations with your doctor.
What should I do if I have high cholesterol or heart disease while waiting for new treatments?
Continue following your doctor’s current treatment plan with proven medications and lifestyle changes. Stay active, eat a heart-healthy diet, manage stress, and take prescribed medications as directed. Discuss new research with your doctor at regular checkups to stay informed about emerging treatments.
Want to Apply This Research?
- Track weekly inflammation markers if you have access to testing (such as C-reactive protein through your doctor), along with cholesterol levels and blood pressure. Record any new heart disease symptoms or changes in existing symptoms. Note medication adherence and any side effects from current treatments.
- While waiting for new treatments to potentially become available, use the app to track proven heart-healthy behaviors: daily steps (aim for 10,000), minutes of moderate exercise, servings of fruits and vegetables, and adherence to current medications. Set reminders for doctor appointments to discuss new research developments.
- Establish a baseline of current health metrics (cholesterol, blood pressure, weight, exercise capacity). Monthly, review trends in these metrics and symptom changes. Quarterly, discuss research updates with your doctor. Use the app to maintain consistency with proven heart-healthy lifestyle changes while new treatments are being developed.
This research is early-stage animal research and has not been tested in humans. Cadd4 is not approved by the FDA and is not available as a treatment. Do not stop or change any current heart disease or cholesterol medications based on this information. Always consult with your healthcare provider before making any changes to your treatment plan. This article is for informational purposes only and should not be considered medical advice. If you have heart disease, high cholesterol, or cardiovascular risk factors, work with your doctor to determine the best proven treatment options for your individual situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.